Our goal is to be the leading global biopharmaceutical company focused on innovative treatments for women’s health and prostate cancer in areas of high unmet medical need, and improve the lives of millions of patients suffering from these diseases.
Our lead investigational program is relugolix, which has been evaluated in more than 2,150 participants and has successfully completed three large, randomized Phase 2 trials in patients with uterine fibroids, endometriosis and prostate cancer. In completed trials, relugolix was generally well tolerated and suppressed estrogen and progesterone levels in women and testosterone levels in men. In addition, we are developing MVT-602 for the treatment of female infertility as part of assisted reproduction. Over time, we intend to expand our development pipeline to include other potential treatments for women’s health and prostate cancer.
